Condensed Consolidated Statement of Equity (USD $)	Preferred Stock [Member]	Common Stock [Member]	Contingently Issuable Shares [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit During Development Stage [Member]	Total TG Therapeutics Inc. and Subsidiaries Equity [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2011	$ 413	$ 5,061	$ 6	$ 10,472,115	$ (853,074)	$ 9,624,521	$ 11,681	$ 9,636,202
Balance (in shares) at Dec. 31, 2011	413,388	5,061,399
Changes during the period:
Compensation in respect of restricted preferred stock granted to employees				188,509		188,509		188,509
Preferred stock issued at $20.00 per share, net of expenses	696			12,180,710		12,181,406		12,181,406
Preferred stock issued at $20.00 per share, net of expenses (in shares)	695,428
Shares issued in subsidiary to non-controlling interest in connection with in-licensing agreement						0	16,578,000	16,578,000
Conversion of preferred stock to common stock in conjunction with reverse stock split	(1,109)	9,858		(8,749)		0		0
Conversion of preferred stock to common stock in conjunction with reverse stock split (in shares)	(1,108,816)	9,857,596
Issuance of restricted stock		5,140		(5,140)		0		0
Issuance of restricted stock (in shares)		5,140,000
Compensation in respect of restricted common stock granted to employees, directors and consultants				1,990,081		1,990,081		1,990,081
Net loss					(14,612,982)	(14,612,982)	(8,067,916)	(22,680,898)
Balance at Sep. 30, 2012	$ 0	$ 20,059	$ 6	$ 24,817,526	$ (15,466,056)	$ 9,371,535	$ 8,521,765	$ 17,893,300
Balance (in shares) at Sep. 30, 2012	0	20,058,995